دورية أكاديمية
Benign T cells drive clinical skin inflammation in cutaneous T cell lymphoma.
العنوان: | Benign T cells drive clinical skin inflammation in cutaneous T cell lymphoma. |
---|---|
المؤلفون: | Vieyra-Garcia P; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.; Research Unit for Photodermatology, Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria., Crouch JD; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., O'Malley JT; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Seger EW; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Yang CH; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Teague JE; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Vromans AM; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Gehad A; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Win TS; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Yu Z; Harvard Medical School, Boston, Massachusetts, USA., Lowry EL; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Na JI; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.; Department of Dermatology, Seoul National University Bundang Hospital, Seongnam, South Korea., Rook AH; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Wolf P; Research Unit for Photodermatology, Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria., Clark RA; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. |
المصدر: | JCI insight [JCI Insight] 2019 Jan 10; Vol. 4 (1). Date of Electronic Publication: 2019 Jan 10. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 101676073 Publication Model: Electronic Cited Medium: Internet ISSN: 2379-3708 (Electronic) Linking ISSN: 23793708 NLM ISO Abbreviation: JCI Insight Subsets: PubMed not MEDLINE; MEDLINE |
أسماء مطبوعة: | Original Publication: Ann Arbor, Michigan : American Society for Clinical Investigation, [2016]- |
مستخلص: | Psoralen plus UVA (PUVA) is an effective therapy for mycosis fungoides (MF), the skin-limited variant of cutaneous T cell lymphoma (CTCL). In low-burden patients, PUVA reduced or eradicated malignant T cells and induced clonal expansion of CD8+ T cells associated with malignant T cell depletion. High-burden patients appeared to clinically improve but large numbers of malignant T cells persisted in skin. Clinical improvement was linked to turnover of benign T cell clones but not to malignant T cell reduction. Benign T cells were associated with the Th2-recruiting chemokine CCL18 before therapy and with the Th1-recruiting chemokines CXCL9, CXCL10, and CXCL11 after therapy, suggesting a switch from Th2 to Th1. Inflammation was correlated with OX40L and CD40L gene expression; immunostaining localized these receptors to CCL18-expressing c-Kit+ dendritic cells that clustered together with CD40+OX40+ benign and CD40+CD40L+ malignant T cells, creating a proinflammatory synapse in skin. Our data suggest that visible inflammation in CTCL results from the recruitment and activation of benign T cells by c-Kit+OX40L+CD40L+ dendritic cells and that this activation may provide tumorigenic signals. Targeting c-Kit, OX40, and CD40 signaling may be novel therapeutic avenues for the treatment of MF. |
معلومات مُعتمدة: | P30 AR069625 United States AR NIAMS NIH HHS; T32 AR007098 United States AR NIAMS NIH HHS; R01 CA122569 United States CA NCI NIH HHS; R01 CA203721 United States CA NCI NIH HHS; R01 AR063962 United States AR NIAMS NIH HHS; R01 AR074797 United States AR NIAMS NIH HHS |
فهرسة مساهمة: | Keywords: Dermatology; Immunology; Lymphomas |
تواريخ الأحداث: | Date Created: 20190111 Latest Revision: 20221110 |
رمز التحديث: | 20221213 |
مُعرف محوري في PubMed: | PMC6485670 |
DOI: | 10.1172/jci.insight.124233 |
PMID: | 30626755 |
قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!